Belgium· BE-AMP-SAM662555-00
Zynyz 500 mg
A retifanlimab product containing retifanlimab, registered in Belgium by Incyte Biosciences Distribution. The same ATC class is registered in 10 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Retifanlimab is registered in 10 of 19 countries.
Countries holding a registration under ATC L01FF10 (retifanlimab), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 7 of them publish a price we can compare per daily dose
Retifanlimab · ATC L01FF10
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Retifanlimab
- Manufacturer
- Incyte Biosciences Distribution
- Country
- Belgium (BE)
- ATC code
- L01FF10
- ATC class
- Retifanlimab
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Retifanlimab in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaZYNYZIncyte Biosciences Distribution B.V., Amsterdam
- FinlandZYNYZIncyte Biosciences Distribution B.V.
- IrelandZynyz 500 mg concentrate for solution for infusionIncyte Biosciences Distribution B.V.
- IcelandZynyzIncyte Biosciences Distribution B.V.
- SwedenZYNYZ 500 mg Koncentrat till infusionsvätska, lösningIncyte Biosciences Distribution B.V.
- United StatesZYNYZIncyte Corporation
- SpainZYNYZ 500 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONIncyte Biosciences Distribution B.V.
- SwitzerlandZYNYZ 500 mg/20 ml, solution à diluer pour perfusionIncyte Biosciences International Sàrl
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Zynyz
- Liechtenstein · Zynyz
- Norway · Zynyz
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a7f19974-426a-412b-aabf-044f07aeb929 GET /v1/drugs/a7f19974-426a-412b-aabf-044f07aeb929?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentrate for solution for infusion",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Zynyz 500 mg",
"name_fr": "Zynyz 500 mg",
"name_nl": "Zynyz 500 mg",
"amp_code": "SAM662555-00",
"strengths": [
"25.0000",
"25.0000"
],
"pack_count": 1,
"substances": [
"Retifanlimab",
"Sodium Acetate Trihydrate",
"Sucrose",
"Polysorbate 80"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Retifanlimab",
"authorisation_numbers": [
"EU/1/24/1800/001"
]
}See everything about retifanlimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.